Tumor shrinkage occurred both in OPGs harboring BRAF fusions and BRAF V600E mutations, and both in patients who had previously received mitogen-activated protein kinase inhibitor (MAPKi) therapy and patients who had not. This evidence concerns the gene WNK2 and neoplasm.